搜索
Nutriband Inc
NTRB添加自选
3.090USD
-0.100-3.13%
收盘 07/01, 16:00（美东）报价延迟15分钟
37.56M总市值
亏损市盈率 TTM
关键数据
3.190今开
3.287最高
24.05K成交量
亏损市盈率 TTM
--市盈率动
--股息TTM
0.20%换手率
3.190昨收
3.030最低
54.09K成交额
亏损市盈率静
6.27市净率
0.00%股息率 TTM
-109.60%ROA
11.67852周最高
1.65量比
-10.48M净利润
12.16M总股本
-2.5809每股收益TTM
1.93Beta
-458.50%ROE
3.20952周最低
8.06%振幅
45.41%毛利率
37.56M总市值
-2.46回报/风险
4.12%风险率
TradingKey Nutriband Inc股票评分
单位: USD 更新时间: 2026-07-01操作建议
Nutriband Inc当前公司基本面数据相对非常健康，增长潜力较大。当前估值合理，在医疗设备与耗材行业排名119/204位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价15.00。中期看，股价处于下降通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Nutriband Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Nutriband Inc亮点
亮点风险
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
业绩增长期
公司处于发展阶段，最新年度总收入2.04M美元
利润高增长
公司净利润处于行业前列，最新年度总收入2.04M美元
估值高估
公司最新PE估值-1.20，处于3年历史高位
机构加仓
最新机构持股579.57K股，环比增加15.48%
分析师目标
根据
1
位分析师
买入
评级
15.000
目标均价
+370.22%
涨幅空间
Nutriband Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Nutriband Inc简介
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
公司代码NTRB
公司Nutriband Inc
CEOMelnik (Serguei)
网址https://nutriband.com/
相关品种
+2.62%
+2.41%
+1.57%
+1.18%
+1.73%
+1.30%
-0.50%
+1.27%
+7.60%
+0.88%
+0.39%
+0.89%
+1.92%
+1.70%
+5.81%
+3.09%
+2.12%
+1.08%
+1.78%
+0.41%热门品种
常见问题
Nutriband Inc(NTRB)的当前股价是多少？
Nutriband Inc(NTRB)的当前股价是 3.09。
Nutriband Inc的股票代码是什么？
Nutriband Inc的股票代码是NTRB。
Nutriband Inc股票的52周最高点是多少？
Nutriband Inc股票的52周最高点是11.68。
Nutriband Inc股票的52周最低点是多少？
Nutriband Inc股票的52周最低点是3.21。
Nutriband Inc的市值是多少？
Nutriband Inc的市值是37.56M。
现在Nutriband Inc(NTRB)的股票是买入、持有还是卖出？
根据分析师评级，Nutriband Inc(NTRB)的总体评级为买入，目标价格为15.00。
Nutriband Inc(NTRB)股票的每股收益（EPS TTM）是多少
Nutriband Inc(NTRB)股票的每股收益（EPS TTM）是-2.58。